Close Menu
As part of its ongoing plan to turn its business from an unprofitable tool shop into a successful diagnostic company, Ciphergen Biosystems has agreed to sell its proteomic tools arm to Bio-Rad for $20 million in cash.
 
The sale, announced this week, would give Bio-Rad Ciphergen’s Surface Enhanced Laser Desorption/Ionization technology, ProteinChip arrays, and accompanying software. Bio-Rad will also buy a $3-million equity stake in the company.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.